Medical Device/ Diagnostic
Carmell Therapeutics (Carmell™) is a regenerative medicine biotech company focused on leveraging our core platform technology, Plasma-based Bioactive Material (“PBM”). PBM is a proprietary formulation of multiple Growth Factors (“GFs”) and other regenerative factors contained in allogeneic platelet-enriched plasma designed to accelerate and enhance healing in bone, skin, and other tissues, and has the potential to stimulate hair regrowth and collagen production after severe injury, disease, or aging. The platform technology of PBM is initially targeted to accelerate and enhance healing in bone applications (orthobiologics); Carmell™ believes PBM has the ability to deliver many regenerative factors in spaces like aesthetic medicine (androgenic alopecia), wound care and dental bone substitute. Carmell™ currently has two PBM product candidates in development – a Bone Healing Accelerant (“BHA”) and a Tissue Healing Accelerant (“THA”). BHA for use in open tibia fracture has been granted “Fast Track” designation by the FDA and clinical development is ongoing.